KPC-39-mediated resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 clinical isolate - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2021

KPC-39-mediated resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 clinical isolate

Bogdan Iorga

Résumé

Resistance to ceftazidime–avibactam (CAZ-AVI) combination is being increasingly reported. Here, we report a CAZ-AVI resistant Klebsiella pneumoniae belonging to the high-risk ST307 clone and producing KPC-39, a single amino-acid variant of KPC-3 (A172T). Cloning experiments, steady state kinetic parameters and molecular dynamics simulations revealed a loss of carbapenemase activity and an increased affinity for ceftazidime. KPC-39 was identified in a patient without prior exposure to CAZ-AVI, suggesting silent dissemination in European healthcare settings.
Fichier principal
Vignette du fichier
AAC01160-21R2-HAL.pdf (603.55 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03366306 , version 1 (05-10-2021)

Identifiants

Citer

Agnès Jousset, Saoussen Oueslati, Cécile Emeraud, Rémy Bonnin, Laurent Dortet, et al.. KPC-39-mediated resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 clinical isolate. Antimicrobial Agents and Chemotherapy, 2021, 65 (12), pp.e0116021. ⟨10.1128/aac.01160-21⟩. ⟨hal-03366306⟩
84 Consultations
55 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More